Literature DB >> 6144549

Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.

H Allgayer, W Kruis, J Eisenburg, G Paumgartner.   

Abstract

Rectal administration of sulphasalazine to patients with ulcerative colitis has recently been shown to have similar therapeutic activity but fewer side effects than oral treatment. The present study is a comparison of the pharmacokinetics of sulphasalazine (SASP) and its metabolite sulphapyridine (SP) after rectal and oral administration of SASP to 6 patients with ulcerative colitis. The areas under the concentration-time curves (AUC) and the maximum concentrations (Cmax) of SASP and SP were significantly lower after rectal than oral administration of SASP (p less than 0.05). These findings support the view that the lower frequency of side effects after rectal administration of SASP may result from the lower plasma levels of SASP and SP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144549     DOI: 10.1007/bf00630300

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

2.  Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.

Authors:  K M Das; M A Eastwood
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

3.  Desensitization of patients with inflammatory bowel disease to sulfasalazine.

Authors:  S L Taffet; K M Das
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

4.  On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon.

Authors:  P Frühmorgen; L Demling
Journal:  Hepatogastroenterology       Date:  1980-12

5.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

6.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

7.  Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.

Authors:  O H Nielsen
Journal:  Scand J Gastroenterol       Date:  1982-04       Impact factor: 2.423

Review 8.  Rectal drug administration: clinical pharmacokinetic considerations.

Authors:  A G de Boer; F Moolenaar; L G de Leede; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

9.  Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.

Authors:  K R Palmer; J R Goepel; C D Holdsworth
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-16

10.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

View more
  3 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

3.  Gut microbiota-driven drug metabolism in inflammatory bowel disease.

Authors:  Femke Crouwel; Hans J C Buiter; Nanne K de Boer
Journal:  J Crohns Colitis       Date:  2020-07-11       Impact factor: 9.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.